RecruitingNot Applicable

Clinical Prognostic Score to Predict Relapse in VL

Ethiopia741 participantsStarted 2023-02-03

Plain-language summary

This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia. Therefore, comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment will be performed in order to identify the factors that determine prognosis of the patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinically or parasitologically confirmed VL Exclusion Criteria: * Age under 12 years * VL patients already on treatment for 3 days or more * Severe critical condition or other circumstances that make the study medically inadvisable * Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information * Pregnant or lactating woman

What they're measuring

Identification of risk factors for relapse

Timeframe: December 2026

Prognostic tool for relapse

Timeframe: December 2026

Trial details

NCT IDNCT05602610

SponsorInstitute of Tropical Medicine, Belgium

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Saskia van Henten, MD

+32(0)32476556 svanhenten@itg.be

View on ClinicalTrials.gov More Visceral Leishmaniasis trials